Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of BI 3032950 in Healthy Subjects
NCT05985200Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3032950 in ulcerative colitis (UC) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event. Started Sep 2023; status: completed.
02
Drugs
BI 3032950
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05985200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985200.